Patents Examined by Sheela J. Huff
  • Patent number: 10266605
    Abstract: The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: April 23, 2019
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Patent number: 10266597
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: April 23, 2019
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Patent number: 10265389
    Abstract: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the protein. More particularly, the method comprises the step of determining the presence or amount of an eEF2 polypeptide or an eEF2 antibody in a sample obtained from a subject.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: April 23, 2019
    Assignee: INTERNATIONAL INSTITUTE OF IMMUNOLOGY, INC.
    Inventors: Haruo Sugiyama, Yusuke Oji
  • Patent number: 10253069
    Abstract: The present invention provides compositions and methods for regulating arterial tone based on the discovery herein of novel expression and regulation of hemoglobin alpha and cytochrome B5 reductase 3 and the effects on NO and NOS.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: April 9, 2019
    Assignee: University of Virginia Patent Foundation
    Inventors: Benjamin M. Gaston, Adam C. Straub, Brant E. Isakson, Linda Columbus
  • Patent number: 10238727
    Abstract: A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Müller, Julia Leibold, Valentina Goldfinger
  • Patent number: 10238656
    Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: March 26, 2019
    Assignee: Eli Lilly and Company
    Inventor: Edward Michael Chan
  • Patent number: 10239947
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Patent number: 10238748
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 26, 2019
    Assignee: Novartis AG
    Inventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
  • Patent number: 10239925
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: March 26, 2019
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10231944
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 19, 2019
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10233214
    Abstract: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 19, 2019
    Assignee: Esperance Pharmaceuticals, Inc.
    Inventors: Carola Leuschner, Hector Alila
  • Patent number: 10227412
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 12, 2019
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Patent number: 10213401
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 26, 2019
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10206989
    Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: February 19, 2019
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Yusuke Tomita, Ryuji Osawa
  • Patent number: 10196454
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: February 5, 2019
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Patent number: 10189881
    Abstract: This disclosure provides an isolated polypeptide comprising no more than 35 amino acids, wherein the amino acid sequence comprises, or alternatively consists essentially of, or alternatively consisting of XXXRYSYXXSYX (SEQ ID NO: 1) and equivalents thereof, wherein X is a basic amino acid and Y is a hydrophobic amino acid. Polynucleotides encoding the polypeptides and antibodies that bind to the polypeptides are also provided. Therapeutic and diagnostic uses are further provided.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: January 29, 2019
    Assignee: The Regents of the University of California
    Inventors: Reen Wu, Ching-Hsien Chen
  • Patent number: 10183982
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: January 22, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 10179165
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 15, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10172875
    Abstract: Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and/or decreased toxicity are also provided.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: January 8, 2019
    Assignee: ImmunoGen, inc.
    Inventors: Jose Ponte, Jan Pinkas, Rodrigo R. Ruiz-Soto
  • Patent number: 10174089
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh